Allogenic Mesenchymal Stem Cell (MSC) Therapy (Instituto De Investigación Biomédica De Salamanca)

N/A

Report date: 2026/05/02 20:00:18

Base Information

Drug NameAllogenic Mesenchymal Stem Cell (MSC) Therapy (Instituto De Investigación Biomédica De Salamanca)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Adipose-derived

Mechanisms of ActionStem cell replacements

TargetsNot applicable

Therapy Area/IndicationsGraft vs Host DiseaseDry Eye Syndromes

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesInstituto De Investigación Biomédica De Salamanca

China Registration ClassN/A

Develop Information

Active CompaniesInstituto De Investigación Biomédica De Salamanca

Inactive CompaniesN/A

Active IndicationsGraft vs Host DiseaseDry Eye Syndromes

Inactive IndicationsN/A

Other Information

ATC CodeN/A